Fenspiride (INN, brand names Eurespal, Pneumorel and others) is an oxazolidinonespiro compound used as a drug in the treatment of certain respiratory diseases.[2] The pharmacotherapeutic classification is antitussives. In Russia it was approved for the treatment of acute and chronic inflammatory diseases of ENT organs (ear, nose, throat) and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as for maintenance treatment of asthma.[3]Russia, Romania, France and other European countries withdrew fenspiride-based drugs from the market due to the risk of QT prolongation and torsades de pointes.[4] Fenspiride is known to have activity as an alpha-1 blocker, H1 antagonist, it also inhibits PDE3, PDE4, PDE5 with -logIC50 values of 3.44, 4.16, 3.8 respectively.[5]
References
^Montes B, Catalan M, Roces A, Jeanniot JP, Honorato JM (1993). "Single dose pharmacokinetics of fenspiride hydrochloride: phase I clinical trial". European Journal of Clinical Pharmacology. 45 (2): 169–72. doi:10.1007/bf00315501. PMID7901024. S2CID20605939.
^Płusa T, Nawacka D (December 1998). "[Efficacy and tolerance of fenspiride in adult patients with acute respiratory tract infections]". Polski Merkuriusz Lekarski. 5 (30): 368–71. PMID10101527.